Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Henan Lingrui Pharmaceutical Co Ltd announces FY 2013 net profit outlook below I/B/E/S estimates


Sunday, 26 Jan 2014 07:00pm EST 

Henan Lingrui Pharmaceutical Co Ltd:Sees net profit for the fiscal year (FY) 2013 to increase by 135 pct to 160 pct, compared to the net profit of the same period in FY 2012 (42,453,610.02 yuan).Says the reason for positive outlook is due to the increased sales and the investment profit.FY 2013 net income of 117.30 million yuan - Thomson Reuters I/B/E/S. 

Company Quote

8.45
0.08 +0.96%
26 Dec 2014